All posts by Genetic Signatures
The 34th ASM Clinical Virology Symposium (CVS) will be held in West Palm Beach, FL on 6th–9th May 2018.
ASM Clinical Virology Symposium is led by biomedical scientists engaged in research as well as primary care physicians and laboratories involved with patient care, this international symposium will provide an unmatched forum for the meaningful exchange of ideas dealing with viral infections.
Visit Genetic Signatures at Booth 312 at ASM CVS 2018 for more information.
Click here to visit the CVS website
GenomeWeb, the largest online newsroom focused on advanced molecular research tools, has featured Genetic Signatures and 3base™ technology, in an article about the company’s continued global market rollout of their existing and new suite of products. The new 3base™ multiplex PCR test includes an assay for detecting an extensive suite of Antimicrobial Resistance- ESBL and CPO Resistance Markers. The GenomeWeb article highlighted Genetic Signatures’ recent European Registration of their new EasyScreenTM ESBL CPO Detection kit, which will be presented at the infectious diseases conference, ECCMID, in April 2018 (Madrid, Spain).
Genetic Signatures’ are proud to announce we will be exhibiting at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 21-24 April 2018 in Madrid, Spain.
It is a pleasure to announce that Medical Scientist, Elaine McGrath from the University Hospital, Galway, has been selected to present a scientific poster titled “Evaluation of the EasyScreenTM CPO 3baseTM real-time PCR assay for detection of Carbapenemase genes directly from rectal swabs.”
The poster will highlight Genetic Signatures’ proprietary 3base™ technology and upcoming EasyScreenTM ESBL/CPO detection kit, which simultaneously identifies 16 of the most common Anti-microbial resistant pathogen strains.
Abstract No: 6682
Session type: Paper Poster Session #P2322
Session name: Detection of carbapenem resistance
Session date: 24/04/2018
Session time: 12:30h – 13:30h CEST
Genetic Signatures will also exhibit the EasyScreen™ products for the detection of infectious diseases, including kits for diagnosing Enteric bacterial, viral and protozoan pathogens, Respiratory pathogens, Sexual Health pathogens, Tropical disease pathogens, and Meningitis.
Visit Genetic Signatures at Booth #83 at ECCMID 2018 for more information. Click here to visit ECCMID 2018
About ESBL and CPO: ESBLs are enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins and monobactams but do not affect cephamycins or carbapenems. The presence of an ESBL-producing organism in a clinical infection can result in treatment failure if one of the above classes of drugs is used. ESBLs can be difficult to detect because they have different levels of activity against various cephalosporins. Thus, the choice of which antimicrobial agents to test is critical. 1
CPO or CRE, which stands for carbapenemase producing organisms or carbapenem-resistant Enterobacteriaceae organisms, are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. Klebsiella species and Escherichia coli (E. coli) are examples of Enterobacteriaceae, a normal part of the human gut bacteria, that can become carbapenem-resistant. Types of CRE are sometimes known as KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi Metallo-beta-lactamase). KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM (Verona Integron-Mediated Metallo-β-lactamase) have also been reported in Pseudomonas.
Healthy people usually do not get CRE infections – they usually happen to patients in hospitals, nursing homes, and other healthcare settings. Patients whose care requires devices like ventilators (breathing machines), urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.
Some CRE bacteria have become resistant to most available antibiotics. Infections with these germs are very difficult to treat, and can be deadly-one report cites they can contribute to death in up to 50% of patients who become infected.2
About the EasyScreen™ Antibiotic Resistance Detection Kit: The EasyScreen™ Antibiotic Resistance Detection Kit detects the most common resistant markers. ESBL and CPO targets that are detected are β –Lactamases TEM, SHV, CTX-M, CMY, DHA, OXA-48 like, OXA- 23 like, OXA-51 like, GES, MCR-1,IMI,SME, , New Delhi Metallo- β –Lactamases (NDM), Klebsiella pneumoniae carbapenemase (KPC), Metallo- β –Lactamases VIM, Metallo- β –Lactamases IMP
About ECCMID: The 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is one of the largest European Infectious diseases meetings. The congress provides a forum for the world’s leading experts who come together to discuss the latest developments in diseases, infection control, and clinical microbiology.
Genetic Signatures’ Chief Scientific Officer, Dr. Doug Millar will be presenting at Medical Microbiology Meeting (MMM) 2018 in Sydney, Australia on April 12th.
MMM provides a forum for research scientists, laboratory staff and clinicians to share the latest issues and developments in the field of molecular microbiology. It has become the principal forum for sharing new molecular diagnostics concepts in Australia. This two-day meeting uses an informal workshop style with encouragement for comments and questions from the floor.
- Thursday 12th April 2018 16:25-16: 35 pm EST
Presentation title: Irish evaluation of the EasyScreen™ ESBL/CPO Detection Kit Using Primary Patient Swabs.
Come along and chat to our team at Genetic Signatures at MMM 2018 Sydney, Australia for more information on our EasyScreenTM Detection Kits and learn more about 3baseTM technology.
Click here to visit the MMM 2018 Sydney website